SG Americas Securities LLC Cuts Position in Krystal Biotech, Inc. $KRYS

SG Americas Securities LLC reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 73.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,318 shares of the company’s stock after selling 9,289 shares during the period. SG Americas Securities LLC’s holdings in Krystal Biotech were worth $586,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Hantz Financial Services Inc. boosted its holdings in Krystal Biotech by 8,950.0% during the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after buying an additional 179 shares in the last quarter. AdvisorNet Financial Inc purchased a new position in Krystal Biotech in the third quarter valued at about $30,000. Salomon & Ludwin LLC acquired a new stake in shares of Krystal Biotech during the 3rd quarter valued at approximately $33,000. First Horizon Advisors Inc. boosted its stake in shares of Krystal Biotech by 212.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after acquiring an additional 166 shares in the last quarter. Finally, Caldwell Trust Co acquired a new stake in shares of Krystal Biotech in the 2nd quarter worth approximately $34,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on KRYS shares. TD Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $310.00 price target (up previously from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Citigroup boosted their price objective on shares of Krystal Biotech from $320.00 to $336.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Chardan Capital raised their target price on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $271.75.

Krystal Biotech Trading Up 1.1%

Krystal Biotech stock opened at $289.13 on Friday. The stock has a 50-day moving average price of $242.60 and a 200 day moving average price of $191.29. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $295.98. The stock has a market cap of $8.38 billion, a PE ratio of 43.35 and a beta of 0.46.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $1.54. The company had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. On average, equities analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the sale, the insider directly owned 1,413,711 shares of the company’s stock, valued at approximately $311,242,613.76. The trade was a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 13.70% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.